Biolidics Ltd, formerly known as Clearbridge BioMedics, is a medical technology company focusing on the development of cell enrichment systems which, when combined with other analytical tests, have a wide range of applications for cancer diagnosis, prognosis, treatment selection and treatment monitoring.
Pioneering patented, award-winning microfluidics technology, Biolidics is leading the advancement of non-invasive liquid biopsy for real time analysis of cancer cells, providing vital and accurate information for higher standard of healthcare treatment in an era of
It is a spin-off from the National University of Singapore (NUS) / SMART MIT and is the first incubatee of Clearbridge Accelerator, a high-technology incubator backed by the Singapore Government’s National Research Foundation (NRF).
The ClearCell® FX1 System by Biolidics provide a label-free means of Circulating Tumour Cell (CTC) enrichment that offers a myriad of possibilities for downstream analysis on the output CTCs.
Utilising patented award-winning microfluidic technologies, Biolidics aims to provide the next generation of non-invasive “liquid biopsy” approaches for cancer screening, diagnosis, staging, personalised medicine and treatment monitoring.
Biolidics currently has customers across Asia, Europe and North America.